BAL - Chart, page-3682

That's a good chart.
I feel more comfortable holding this until SAMR.
The launch of new products should easily guarantee BAL meets guidance. Add in SAMR and they will smash FY20 guidance.

Considering the result was dismal, the outlook is not that bad. This was one of the best investor presentations I have read in a long time. Looks like BAL has many avenues to succeed in FY20:
1. New formula already seen an upswing in Q4 sales.
2. ViPlus
3. Vietnam (up to 12 months). Philippines & Indonesia (up to 6 months)
4. SAMR opens the door to China
5. Expanded product range including goat milk formula to rival BUB

Apart from FY19 missing guidance upside now looks close to certain. Watch more institutions start to accumulate and shorters exit in droves.